Helixgate

Helixgate

Uncategorized

STAT+: 7 key issues we’re watching as RFK Jr. faces a Congressional gauntlet

WASHINGTON — Health secretary Robert F. Kennedy Jr. has a delicate task ahead of him as he heads to Capitol Hill to testify about the fiscal 2027 budget request: Stick to the White House’s script on Make America Healthy Again “wins” while avoiding politically divisive topics like vaccines. 

How he navigates lawmakers’ questions over at least seven hearings will test whether the secretary can stay on message before he embarks on a midterms tour to shore up support for the MAHA movement and the White House’s agenda. 

Thursday’s hearings are Kennedy’s first since a heated Senate health committee appearance in September, where tempers rose as Kennedy defended his firing of Centers for Disease Control and Prevention Director Susan Monarez. 

Continue to STAT+ to read the full story…

Read More

Published

on

WASHINGTON — Health secretary Robert F. Kennedy Jr. has a delicate task ahead of him as he heads to Capitol Hill to testify about the fiscal 2027 budget request: Stick to the White House’s script on Make America Healthy Again “wins” while avoiding politically divisive topics like vaccines. 

How he navigates lawmakers’ questions over at least seven hearings will test whether the secretary can stay on message before he embarks on a midterms tour to shore up support for the MAHA movement and the White House’s agenda. 

Thursday’s hearings are Kennedy’s first since a heated Senate health committee appearance in September, where tempers rose as Kennedy defended his firing of Centers for Disease Control and Prevention Director Susan Monarez. 

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

How Trump is pushing psychedelics reform through the health agencies

WASHINGTON — President Trump moved on Saturday to “reverse the crisis of serious mental illness in America” by boosting access to psychedelic drugs in clinical settings. In an executive order, he directed the federal government to rush access to treatments and reevaluate their status as controlled substances.

The order directs the Food and Drug Administration to expedite some psychedelics as breakthrough drugs, as well as allowing them to be used through right-to-try legislation, which allow terminally ill patients to try experimental drugs outside of usual regulatory pathways.

Read the rest…

Read More

Published

on

WASHINGTON — President Trump moved on Saturday to “reverse the crisis of serious mental illness in America” by boosting access to psychedelic drugs in clinical settings. In an executive order, he directed the federal government to rush access to treatments and reevaluate their status as controlled substances.

The order directs the Food and Drug Administration to expedite some psychedelics as breakthrough drugs, as well as allowing them to be used through right-to-try legislation, which allow terminally ill patients to try experimental drugs outside of usual regulatory pathways.

Read the rest…

Read More

Continue Reading

Uncategorized

Optimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role

The nomination of a new leader for the Centers for Disease Control and Prevention — one who has scientific credentials and no public ties to the anti-vaccine movement — has generated sighs of relief in the public health world. 

As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but hopeful.”

Read the rest…

Read More

Published

on

The nomination of a new leader for the Centers for Disease Control and Prevention — one who has scientific credentials and no public ties to the anti-vaccine movement — has generated sighs of relief in the public health world. 

As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but hopeful.”

Read the rest…

Read More

Continue Reading

Uncategorized

RevMed’s stunning success; FDA to reclassify peptides; and more

RevMed’s stunning success; FDA to reclassify peptides; and more

Published

on

Welcome back to Endpoints Weekly! Q1 earnings season is officially upon us. Max Gelman kicked off our coverage this week with a story about Johnson & Johnson’s confidence in navigating biosimilar competition …​ ​Read More

Continue Reading
Advertisement

Trending